Latest 20 stories · newest Oct 30, 2026
Third-quarter revenues climbed 10.3% to $17.4 billion; shares rose on the news. The company increased its adjusted earnings per share full-year guidance and announced a 5.2% dividend hike.
AbbVie raised its full-year adjusted diluted earnings per share band by $0.05-$0.09, largely due to a $216 million non-GAAP acquired IPR&D and milestones expense, though this is expected to drop off in 2027.
AbbVie priced $12.05 billion in aggregate face value of senior notes across multiple series, arranged by Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC, and SG Americas Securities, LLC.
AbbVie reported Q2 2026 net revenues of $16.99 billion, a 10.2% increase, and updated its adjusted EPS guidance to $13.87-$14.07.
AbbVie Inc. announced revised adjusted diluted EPS guidance of $13.91 to $14.11 for full-year 2026. The updated outlook incorporates a $291 million expense for acquired IPR&D and milestones, slightly lowering expectations from prior forecasts.
The same ABBV feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ABBV/newsSTART FREE